ID: ALA2165611

Max Phase: Preclinical

Molecular Formula: C10H8Br2N2O2

Molecular Weight: 347.99

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=c1cc(COc2cc(Br)cc(Br)c2)[nH][nH]1

Standard InChI:  InChI=1S/C10H8Br2N2O2/c11-6-1-7(12)3-9(2-6)16-5-8-4-10(15)14-13-8/h1-4H,5H2,(H2,13,14,15)

Standard InChI Key:  KJDCGYZKXMDMOC-UHFFFAOYSA-N

Associated Targets(Human)

Superoxide dismutase 173 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 347.99Molecular Weight (Monoisotopic): 345.8953AlogP: 2.81#Rotatable Bonds: 3
Polar Surface Area: 57.88Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.55CX Basic pKa: CX LogP: 2.22CX LogD: 2.01
Aromatic Rings: 2Heavy Atoms: 16QED Weighted: 0.90Np Likeness Score: -0.66

References

1. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB..  (2012)  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,  55  (1): [PMID:22191331] [10.1021/jm2014277]

Source